Kura’s stock jumps on PhIb readout; FDA lifts hold on INmune Bio program; Nanobiotix’s $20M milestone

Plus, news about Iterum Ther­a­peu­tics, As­tria Ther­a­peu­tics, Aqemia, Ake­bia Ther­a­peu­tics, Tour­ma­line Bio and Ve­ra Ther­a­peu­tics:

Ku­ra On­col­o­gy’s pos­i­tive PhIb read­out: The com­pa­ny is test­ing its in-house menin in­hibitor drug, ziftomenib, in com­bi­na­tion with dif­fer­ent stan­dards of care in 20 pa­tients with acute myeloid leukemia. All five pa­tients re­ceiv­ing one form of stan­dard of care plus ziftomenib achieved a com­plete re­sponse, while 8 of 15 who re­ceived a dif­fer­ent stan­dard of care reg­i­men al­so re­spond­ed to the com­bo. There were no dif­fer­en­ti­a­tion syn­drome events re­port­ed, Ku­ra said. As of the Jan. 11 da­ta cut­off, 16 of 20 pa­tients re­main in the tri­al. Ku­ra’s stock $KU­RA gained about 14% on Tues­day morn­ing. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.